- Home
- IPHA vs TVGN Comparison
IPHA vs TVGN Comparison
Compare IPHA & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- TVGN
- Stock Information
- Founded
- IPHA 1999
- TVGN 2020
- Country
- IPHA France
- TVGN United States
- Employees
- IPHA N/A
- TVGN N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- TVGN Blank Checks
- Sector
- IPHA Health Care
- TVGN Finance
- Exchange
- IPHA Nasdaq
- TVGN Nasdaq
- Market Cap
- IPHA 160.1M
- TVGN 179.0M
- IPO Year
- IPHA 2019
- TVGN N/A
- Fundamental
- Price
- IPHA $1.95
- TVGN $0.74
- Analyst Decision
- IPHA Hold
- TVGN Strong Buy
- Analyst Count
- IPHA 2
- TVGN 1
- Target Price
- IPHA $2.00
- TVGN $10.00
- AVG Volume (30 Days)
- IPHA 21.4K
- TVGN 553.2K
- Earning Date
- IPHA 09-17-2025
- TVGN 11-18-2025
- Dividend Yield
- IPHA N/A
- TVGN N/A
- EPS Growth
- IPHA N/A
- TVGN N/A
- EPS
- IPHA N/A
- TVGN N/A
- Revenue
- IPHA $14,839,695.00
- TVGN N/A
- Revenue This Year
- IPHA $350.96
- TVGN N/A
- Revenue Next Year
- IPHA $32.92
- TVGN N/A
- P/E Ratio
- IPHA N/A
- TVGN N/A
- Revenue Growth
- IPHA N/A
- TVGN N/A
- 52 Week Low
- IPHA $1.29
- TVGN $0.26
- 52 Week High
- IPHA $3.51
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- IPHA 50.85
- TVGN 41.73
- Support Level
- IPHA $1.95
- TVGN $0.64
- Resistance Level
- IPHA $2.10
- TVGN $0.81
- Average True Range (ATR)
- IPHA 0.07
- TVGN 0.06
- MACD
- IPHA 0.02
- TVGN -0.00
- Stochastic Oscillator
- IPHA 66.09
- TVGN 49.46
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.